英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate . . .
    Therefore, this study aimed to investigate the indications for surgical resection as a prognostic factor following NAT with gemcitabine and S-1 (NATGS) Methods: In this retrospective cohort study, we examined patients who underwent curative pancreatic resection following NATGS at our institution between April 2018 and December 2023
  • Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant . . .
    Abstract Background Carbohydrate antigen (CA) 19–9 levels after resection are considered to predict prognosis; however, the significance of decreased CA19–9 levels after neoadjuvant therapy has not been clarified This study aimed to define the prognostic significance of decreased CA19–9 levels after neoadjuvant therapy in patients with pancreatic adenocarcinoma Methods Between 2001 and
  • Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after . . .
    Background: The association between optimal carbohydrate antigen (CA) 19-9 concentration after neoadjuvant chemotherapy (NACT) and prognosis has not been confirmed in patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC)
  • Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate . . .
    Homma Y, Miyake K, Kikuchi Y, Yabushita Y, Matsuyama R, Endo I Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate Antigen 19-9 Levels in Patients With Resectable Pancreatic Cancer Treated With S-1 and Gemcitabine: A Retrospective Cohort Study
  • Post-neoadjuvant treatment pancreatic cancer resectability and outcome . . .
    Background CT prediction of resectability and prognosis following neoadjuvant treatment (NAT) in patients with pancreatic ductal adenocarcinoma (PDAC) remains challenging This study aims to determine whether addition of 18F-fluorodeoxyglucose (FDG) postiron emission tomography (PET) MRI and carbohydrate antigen (CA) 19–9 to contrast-enhanced CT (CECT) can improve accuracy of predicting
  • Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients . . .
    Background: Carbohydrate antigen 19-9 (CA19-9) is a widely used tumor marker for pancreatic ductal adenocarcinoma (PDAC) In addition, several studies have reported the utility of both pre- and postoperative CA19-9 levels as prognostic factors in resectable PDAC
  • Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients . . .
    Carbohydrate antigen 19-9 (CA19-9) is a widely used tumor marker for pancreatic ductal adenocarcinoma (PDAC) In addition, several studies have reported the utility of both pre- and postoperative CA19-9 levels as prognostic factors in resectable PDAC However, little is known about the implications of post-adjuvant chemotherapy (AC) CA19-9 levels The purpose of this study was to examine the
  • Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival . . .
    This study evaluates the prognostic role of carbohydrate antigen 19 to 9 (CA19-9) in predicting survival of pancreatic cancer patients Literature search was conducted in electronic databases (Google Scholar, Ovid, PubMed, and Science Direct) and study selection was based on precise eligibility criteria
  • Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate . . .
    Abstract Carbohydrate antigen 19-9 (CA19-9) is widely used to assess treatment response and monitor recurrence alongside imaging However, the criteria for determining resectability after completion of neoadjuvant therapy (NAT) remain poorly defined Therefore, this study aimed to investigate the indications for surgical resection as a prognostic factor following NAT with gemcitabine and S-1
  • The prognostic value of CA19-9 response after neoadjuvant . . . - Springer
    Background Pancreatic cancer (PC) is a highly aggressive and refractory disease, with disappointing 5-year survival rates Regarding the wide application of neoadjuvant treatment in patients with PC, how the post-neoadjuvant Carbohydrate antigen 19-9 (CA19-9) response could translate into a survival benefit is not clearly understood We aimed to evaluate the correlation of the CA19-9 response





中文字典-英文字典  2005-2009